紫杉醇联合洛铂在食管癌新辅助化疗中的疗效观察  

作　　者：张丽[1] 张恒[1] 韩斌[1] 赵鹏[1] 

机构地区：[1]吉林市中心医院,吉林吉林132011

出　　处：《成都医学院学报》2012年第03Z期95-96,共2页Journal of Chengdu Medical College

摘　　要：目的：评价紫杉醇＋洛铂在食管癌术前化疗中的疗效及不良反应。方法：89例患者在食管切除术前采用洛铂＋紫杉醇化疗。在完成2个周期后行食管癌切除术。结果：在行紫杉醇＋洛铂方案治疗过程中，患者耐受性良好，完全缓解49例（55％），部分缓解36例（40％），无效4例（4％）。约90％的患者在手术后肿瘤组织得到完全切除，中位生存期为24个月，1、2、3年的生存率分别为85％、56％和34％。结论：紫杉醇＋洛铂方案用于局部食管癌患者的术前治疗非常合理。Objective To evaluate the efficacy and adverse reactions of combination chemotherapy with paclitaxel plus Lobaplatin in the preoperative chemotherapy. Methods 89 patients have been administrated with Lobaplatin plus paclitaxel before esophagectomy. Results During the treatment proecssof TP regimen, This Lobaplatin - based preoperative regimen, which contained paclitaxel, was well tolerated. Complete remission in 49 cases （55%）, partial remission in 36 cases （40%）, failed 4cases （4%）. approximately 90% of patients tumor completely resected after surgery. The median survival of 24 months, andl, 2, 3 -year survival rates were 85% , 56% and 34%respectively. Conclusion This regi- men is a reasonable preoperative approach for patients with localized esophagealcarcinoma

关 键 词：食管肿瘤 化疗 洛铂 紫杉醇 

分 类 号：R735.1[医药卫生—肿瘤]